PCC Rokita Future Growth
Future criteria checks 2/6
PCC Rokita is forecast to grow earnings and revenue by 11.6% and 5.6% per annum respectively. EPS is expected to grow by 8% per annum. Return on equity is forecast to be 11.8% in 3 years.
Key information
11.6%
Earnings growth rate
8.0%
EPS growth rate
Chemicals earnings growth | 23.8% |
Revenue growth rate | 5.6% |
Future return on equity | 11.8% |
Analyst coverage | Low |
Last updated | 22 Aug 2024 |
Recent future growth updates
Recent updates
Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?
May 30Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Aug 24PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 29Is PCC Rokita (WSE:PCR) A Risky Investment?
Jan 18PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23
Apr 16Why We Like The Returns At PCC Rokita (WSE:PCR)
Mar 19What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?
Jan 25We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)
Sep 01Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching
Jun 14Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?
May 18Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The Brakes
Apr 13Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They Seem
Mar 23PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Mar 09Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?
Feb 19What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?
Feb 04Is PCC Rokita (WSE:PCR) Using Too Much Debt?
Jan 15Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?
Dec 30Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three Years
Dec 17PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Dec 03Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?
Nov 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,441 | 192 | 195 | 408 | 3 |
12/31/2025 | 2,377 | 147 | 125 | 334 | 3 |
12/31/2024 | 2,140 | 76 | 101 | 322 | 2 |
6/30/2024 | 2,048 | 158 | 212 | 376 | N/A |
3/31/2024 | 2,100 | 144 | 111 | 310 | N/A |
12/31/2023 | 2,388 | 268 | 296 | 512 | N/A |
9/30/2023 | 2,782 | 473 | 511 | 736 | N/A |
6/30/2023 | 3,072 | 589 | 623 | 883 | N/A |
3/31/2023 | 3,225 | 692 | 691 | 941 | N/A |
12/31/2022 | 3,143 | 675 | 563 | 792 | N/A |
9/30/2022 | 2,821 | 569 | 392 | 621 | N/A |
6/30/2022 | 2,560 | 499 | 383 | 575 | N/A |
3/31/2022 | 2,405 | 472 | 399 | 553 | N/A |
12/31/2021 | 2,203 | 417 | 380 | 530 | N/A |
9/30/2021 | 2,027 | 294 | 328 | 468 | N/A |
6/30/2021 | 1,827 | 247 | 267 | 389 | N/A |
3/31/2021 | 1,597 | 171 | 200 | 342 | N/A |
12/31/2020 | 1,476 | 117 | 195 | 366 | N/A |
9/30/2020 | 1,414 | 73 | 149 | 340 | N/A |
6/30/2020 | 1,461 | 82 | 136 | 357 | N/A |
3/31/2020 | 1,482 | 72 | 123 | 355 | N/A |
12/31/2019 | 1,492 | 93 | 77 | 310 | N/A |
9/30/2019 | 1,513 | 145 | 81 | 316 | N/A |
6/30/2019 | 1,503 | 160 | 55 | 295 | N/A |
3/31/2019 | 1,512 | 201 | 82 | 356 | N/A |
12/31/2018 | 1,490 | 227 | 41 | 287 | N/A |
9/30/2018 | 1,445 | 243 | 18 | 254 | N/A |
6/30/2018 | 1,378 | 215 | -1 | 220 | N/A |
3/31/2018 | 1,345 | 213 | N/A | 181 | N/A |
12/31/2017 | 1,286 | 182 | N/A | 204 | N/A |
9/30/2017 | 1,234 | 208 | N/A | 264 | N/A |
6/30/2017 | 1,187 | 213 | N/A | 264 | N/A |
3/31/2017 | 1,129 | 207 | N/A | 259 | N/A |
12/31/2016 | 1,107 | 203 | N/A | 263 | N/A |
9/30/2016 | 1,084 | 135 | N/A | 220 | N/A |
6/30/2016 | 1,097 | 131 | N/A | 187 | N/A |
3/31/2016 | 1,077 | 110 | N/A | 161 | N/A |
12/31/2015 | 1,049 | 85 | N/A | 149 | N/A |
9/30/2015 | 1,053 | 73 | N/A | 123 | N/A |
6/30/2015 | 1,062 | 62 | N/A | 130 | N/A |
3/31/2015 | 1,083 | 62 | N/A | 119 | N/A |
12/31/2014 | 1,093 | 71 | N/A | 165 | N/A |
9/30/2014 | 1,066 | 58 | N/A | 117 | N/A |
6/30/2014 | 1,041 | 48 | N/A | 96 | N/A |
3/31/2014 | 1,085 | 52 | N/A | 98 | N/A |
12/31/2013 | 1,101 | 58 | N/A | 104 | N/A |
9/30/2013 | 1,157 | 232 | N/A | 81 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PCR's forecast earnings growth (11.6% per year) is above the savings rate (3.9%).
Earnings vs Market: PCR's earnings (11.6% per year) are forecast to grow slower than the Polish market (14.6% per year).
High Growth Earnings: PCR's earnings are forecast to grow, but not significantly.
Revenue vs Market: PCR's revenue (5.6% per year) is forecast to grow faster than the Polish market (4.3% per year).
High Growth Revenue: PCR's revenue (5.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PCR's Return on Equity is forecast to be low in 3 years time (11.8%).